Medicines Australia has today welcomed the publication of the Department of Health’s annual report, showing net expenditure on the Pharmaceutical Benefits Scheme has risen by over 4% in 2018-19 to A$9.8 billion ($6.71 billion).
“Medicines Australia and our members understand the immense value gained from investing in new medicines and expanding indications, to make medicines available to more Australian patients when they need them,” said Medicines Australia chief executive Elizabeth de Somer.
“We know that investing in listing new medicines and expanded indications is an investment worth making and we are pleased that the additional investment in the PBS, demonstrated in the Department of Health annual report, is a signal that this is being recognized by government.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze